BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  ICER Rejects Molnupiravir For Outpatient COVID Treatment

  ICER recommended two out of three outpatient treatments for COVID-19 in today’s market, singling out molnupiravir as having inadequate evidence that it is better than symptomatic care.

  May 11, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Global Roundup: Medtronic Kicks Off Aortic Stenosis Study in Japan

  Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.

  May 11, 2022

   · 

  8 min read

   · 

  Alex Keown
• 

  Policy

  Cell and Gene Therapy Tackles COVID-19, Potency Assays and Access at ISCT

  With regulatory approvals beginning to break through, attendees at ISCT’s annual meeting set out along the translational pathway. Organizers shared their findings with BioSpace.

  May 11, 2022

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Career Advice

  How to Navigate a Career Change From Biotech To Pharma

  BioSpace spoke with industry experts to find out the differences between working in pharma and biotech and how to know if a pharma company is right for you.

  May 11, 2022

   · 

  5 min read

   · 

  Christie Adams
• 

  Business

  FDA Approves Lilly and Incyte’s Olumiant For Hospitalized COVID-19 Patients

  The FDA has given approval for the commercialization of Eli Lilly and Company and Incyte’s Olumiant, setting a precedent for upcoming COVID-19 treatments.

  May 11, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano
• 

  Drug Development

  Takeda Drops One Hunter Syndrome Therapeutic, Puts Faith in Another

  In its financial results for 2021, Takeda announced that it has decided to discontinue the development of TAK-609, a therapeutic for Hunter Syndrome.

  May 11, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Business

  Nuvig Launches with $47M to Restore Homeostasis to Autoimmunity

  Nuvig plans to use its funding to advance its lead molecule, complete some pre-IND enabling studies and move the molecule to the clinic to begin Phase I studies.

  May 11, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Roche NSCLC Data Doesn’t Bode Well for Anti-TIGIT Immunotherapies

  Genentech (Roche) reported Wednesday that its Phase III SKYSCRAPER-01 trial failed to meet its co-primary endpoint of progression-free survival (PFS).

  May 11, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Inovio Taps New CEO, Drops COVID-19 Vaccine Candidate

  Jacqueline Shea will take over as the new CEO and announced plans to discontinue its Phase III Innovate trial to prioritize its heterologous booster strategy for COVID-19.

  May 11, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Policy

  Congressional Report Claims Emergent Mishap Destroyed 400 Million Doses of J&J Vaccine

  An investigation conducted by the U.S. House of Representatives shows Emergent was forced to destroy nearly 400 million doses of the vaccine. The company disputes the report’s claim.

  May 11, 2022

   · 

  3 min read

   · 

  Alex Keown